Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mycophenolate Mofetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 known ✓ | P12268 | 19/20 | 0.70 |
| ▸ | IMPDH1 known ✓ | P20839 | 14/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mycophenolate Mofetil SCHEMBL29645056 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL29378681 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL4195 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL28390 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL29571382 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL23581135 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL10262894 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL1235420 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL2257852 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL3016437 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6050 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | claimed |
| CN-122060073-A | Chimeric shuttle receptors | 深圳市湾岛细胞科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122029285-A | Methods of treating hypertrophic cardiomyopathy with AAV gene therapy vectors and therapeutic formulations | 迪纳柯公司 | 2026-05-12 | — | — | CN | claimed |
| EP-3463225-B1 | NINTEDANIB FOR REDUCING SCAR FORMATION AT THE SITE OF GLAUCOMA FILTRATION SURGERY | ADS THERAPEUTICS LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260023070-A1 | OPTOGENETIC ALPHA-SYNUCLEIN AGGREGATION SYSTEM-BASED COMPOUND SCREENING PLATFORM IN PD-hiPSC-mDA NEURONS | UNIV JOHNS HOPKINS (US) | 2026-01-22 | — | — | US | claimed |
| EP-3893890-B1 | GINSENOSIDE M1 FOR USE IN THE TREATMENT OF DAMAGES IN ORGANS OR TISSUES IN A SUBJECT CAUSED BY INFECTION WITH CORONAVIRUS | LEE SHEAU LONG (TW) | 2025-12-10 | — | — | EP | claimed |
| US-20250342963-A1 | BOOSTING THE PREDICTIVE POWER OF VIRUS-SPECIFIC T-CELL (VST) CLINICAL TRIALS VIA GENERATIVE MODELS | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2025-11-06 | — | — | US | claimed |
| WO-2025226628-A1 | USE OF IL-6 INHIBITORS FOR PREVENTING OR INHIBITING LUNG TRANSPLANTATION REJECTION IN A SUBJECT | Recordati Rare Diseases Inc. (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250312457-A1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS BLENDS OF WATER-MISCIBLE, PHARMACEUTICALLY ACCEPTABLE SOLVENTS | ARCUTIS BIOTHERAPEUTICS INC (US) | 2025-10-09 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-6225073-B1 | USING MONOCLONAL ANTIBODY THAT CAN DISTINGUISH BETWEEN MYCOPHENOLIC ACID AND ITS ESTERS; FOR MONITORING BIOAVAILABILITY | DADE BEHRING MARBURG GMBH (DE) | 2001-05-01 | — | — | US | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| EP-0988321-A2 | B7-BINDING MOLECULES FOR TREATING IMMUNE DISEASES | INNOGENETICS N.V. (BE) | 2000-03-29 | — | — | EP | claimed |
| EP-0952820-A1 | PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-03 | — | — | EP | claimed |
| CN-1222911-A | Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation | PHARMACIA & UPJOHN SPA (IT) | 1999-07-14 | — | — | CN | claimed |
| WO-1998058965-A2 | B7-BINDING MOLECULES FOR TREATING IMMUNE DISEASES | INNOGENETICS N.V. (BE) | 1998-12-30 | — | — | WO | claimed |
| EP-0724581-B1 | CRYSTALLINE ANHYDROUS MYCOPHENOLATE MOFETIL AND INTRAVENOUS FORMULATION THEREOF | SYNTEX INC (US) | 1998-11-18 | — | — | EP | claimed |
| WO-1998016204-A1 | PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-23 | — | — | WO | claimed |
| EP-0769149-A1 | IMMUNOASSAY FOR MYCOPHENOLIC ACID | BEHRINGWERKE AG (DE) | 1997-04-23 | — | — | EP | claimed |
| WO-1996002004-A1 | IMMUNOASSAY FOR MYCOPHENOLIC ACID | BEHRINGWERKE AG (DE) | 1996-01-25 | — | — | WO | claimed |